Role of biomarkers in monitoring antiblastic cardiotoxicity
Giuseppina Novo(AOL (United States)), Maria Penco(University of Messina), Pasquale Pagliaro(Istituto Nazionale per le Ricerche Cardiovascolari), Concetta Zito(University of Messina), Luca Longobardo(University of Messina), Carlo G. Tocchetti(Federico II University Hospital), Silvio Romano(University of Messina), Savina Nodari(British Heart Foundation), Vincenzo Sucato(University of Palermo)
Cited by 24
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693